Markus A. Seeliger
Cited by
Cited by
How does a drug molecule find its target binding site?
Y Shan, ET Kim, MP Eastwood, RO Dror, MA Seeliger, DE Shaw
Journal of the American Chemical Society 133 (24), 9181-9183, 2011
Activation of tyrosine kinases by mutation of the gatekeeper threonine
M Azam, MA Seeliger, NS Gray, J Kuriyan, GQ Daley
Nature structural & molecular biology 15 (10), 1109-1118, 2008
Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680
MA Young, NP Shah, LH Chao, M Seeliger, ZV Milanov, WH Biggs III, ...
Cancer research 66 (2), 1007-1014, 2006
Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms
N Jura, X Zhang, NF Endres, MA Seeliger, T Schindler, J Kuriyan
Molecular cell 42 (1), 9-22, 2011
A conserved protonation-dependent switch controls drug binding in the Abl kinase
Y Shan, MA Seeliger, MP Eastwood, F Frank, H Xu, Mě Jensen, RO Dror, ...
Proceedings of the National Academy of Sciences 106 (1), 139-144, 2009
High yield bacterial expression of active c‐Abl and c‐Src tyrosine kinases
MA Seeliger, M Young, MN Henderson, P Pellicena, DS King, AM Falick, ...
Protein Science 14 (12), 3135-3139, 2005
Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones
JP Maianti, A McFedries, ZH Foda, RE Kleiner, XQ Du, MA Leissring, ...
Nature 511 (7507), 94-98, 2014
A conserved mechanism of DEAD-box ATPase activation by nucleoporins and InsP6 in mRNA export
B Montpetit, ND Thomsen, KJ Helmke, MA Seeliger, JM Berger, K Weis
Nature 472 (7342), 238-242, 2011
c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty
MA Seeliger, B Nagar, F Frank, X Cao, MN Henderson, J Kuriyan
Structure 15 (3), 299-311, 2007
Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase
B Nagar, O Hantschel, M Seeliger, JM Davies, WI Weis, G Superti-Furga, ...
Molecular cell 21 (6), 787-798, 2006
Mechanism of CDK5/p25 binding by CDK inhibitors
M Mapelli, L Massimiliano, C Crovace, MA Seeliger, LH Tsai, L Meijer, ...
Journal of medicinal chemistry 48 (3), 671-679, 2005
Divergent allosteric control of the IRE1α endoribonuclease using kinase inhibitors
L Wang, BGK Perera, SB Hari, B Bhhatarai, BJ Backes, MA Seeliger, ...
Nature chemical biology 8 (12), 982-989, 2012
Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations
MA Seeliger, P Ranjitkar, C Kasap, Y Shan, DE Shaw, NP Shah, ...
Cancer research 69 (6), 2384-2392, 2009
Structural basis for the recognition of c-Src by its inactivator Csk
NM Levinson, MA Seeliger, PA Cole, J Kuriyan
Cell 134 (1), 124-134, 2008
Three different binding sites of Cks1 are required for p27-ubiquitin ligation
D Sitry, MA Seeliger, TK Ko, D Ganoth, SE Breward, LS Itzhaki, M Pagano, ...
Journal of Biological Chemistry 277 (44), 42233-42240, 2002
A dynamically coupled allosteric network underlies binding cooperativity in Src kinase
ZH Foda, Y Shan, ET Kim, DE Shaw, MA Seeliger
Nature communications 6 (1), 5939, 2015
Targeting conformational plasticity of protein kinases
M Tong, MA Seeliger
ACS chemical biology 10 (1), 190-200, 2015
Structural and functional analysis of the allosteric inhibition of IRE1α with ATP-competitive ligands
HC Feldman, M Tong, L Wang, R Meza-Acevedo, TA Gobillot, I Lebedev, ...
ACS chemical biology 11 (8), 2195-2205, 2016
Tuning a three-component reaction for trapping kinase substrate complexes
AV Statsuk, DJ Maly, MA Seeliger, MA Fabian, WH Biggs III, DJ Lockhart, ...
Journal of the American Chemical Society 130 (51), 17568-17574, 2008
Fibronectin interaction and enhancement of growth factors: importance for wound healing
KM Sawicka, M Seeliger, T Musaev, LK Macri, RAF Clark
Advances in wound care 4 (8), 469-478, 2015
The system can't perform the operation now. Try again later.
Articles 1–20